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“No one can construct for you the bridge upon which  
precisely you must cross the stream of life,  
no one but you yourself alone.”  
 
Friedrich Nietzsche 
 
  
  
ABSTRACT 
Each day, our lungs inhale thousands of liters of air containing not only essential 
oxygen but also smoke particles, dust, allergens, and potentially dangerous 
pathogens. In order to tolerate harmless antigens and initiate an immune response 
against pathogens, a well-organized network of immune cells is required in the 
respiratory tract. Mononuclear phagocytes (MNPs), comprised of macrophages, 
monocytes, and dendritic cells, line the respiratory mucosa and are equipped with 
tools to recognize and rapidly respond to foreign materials. Despite MNPs act as 
sentinels at the mucosal barrier, infections and inflammation can affect the lungs. 
Pulmonary sarcoidosis is a T cell-driven inflammatory disease characterized by 
granuloma formation. The causative antigen is yet to be identified but MNPs are 
known to be involved in the pathogenesis of sarcoidosis. A theory is that the antigen 
is taken up by macrophages. Macrophages also produce vast amounts of the pro-
inflammatory cytokine tumor necrosis factor (TNF). Dendritic cells on the other hand, 
take up the antigen and transport it to the lymph nodes where they activate naïve T 
cells. Circulating monocytes have an important role in cytokine production. However, 
the role of respiratory monocytes during sarcoidosis is less well studied. We 
hypothesized that pulmonary MNPs are crucial in maintaining a steady state of anti- 
and pro-inflammatory processes in healthy individuals. This dynamic process is 
disturbed during sarcoidosis, thereby contributing to pathogenesis. Hence, our aim 
was to study MNPs in the respiratory tract during steady state and sarcoidosis.  
First, we investigated MNPs in the human respiratory tract. We found profound 
differences in distribution of seven MNP subsets between blood and the respiratory 
tract both during steady state and sarcoidosis. We observed an increase in 
frequencies of blood and respiratory monocytes in sarcoidosis patients compared to 
healthy controls. Additionally, monocytes from sarcoidosis patients showed an 
inflammatory profile with upregulation of genes related to inflammatory pathways. 
Intriguingly, MNPs from the lungs of sarcoidosis patients produced TNF without 
external stimulation to a significantly higher degree than that of MNPs from healthy 
controls. In contrast to previous observations, we found that pulmonary monocytes 
contributed more to TNF production than macrophages. Additionally, we associated 
higher frequencies of monocytes in the circulation as well as high numbers of 
intrinsically TNF producing monocytes at time of diagnosis with progressive disease 
development in sarcoidosis.  
In conclusion, we have mapped the MNP network in several anatomical locations of 
the respiratory tract during steady state and sarcoidosis. We also identified pulmonary 
monocytes to play an important role in disease pathogenesis in sarcoidosis. That 
knowledge can help to design new treatment options in sarcoidosis to favor disease 
resolution and improve quality of life.  
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1 INTRODUCTION 
For the human species to exist in nature, evolution has created physical, chemical, 
and cellular barriers in the body to protect itself from the environment. The field of 
immunology studies the body’s immune response against pathogens. Additionally, the 
human immune system in its diversity and specificity has developed mechanisms to 
tolerate the body’s own structures in order to protect it from “self-destruction.” The 
immune system is highly complex and the defense or tolerogenic mechanisms do not 
always work perfectly. Thus, studies of the immune system during healthy and disease 
conditions are required. Understanding the immune system allows to target and to 
manipulate it, thereby increasing future therapeutic options. 
The immune system spans throughout each organ of the body. It can be divided into 
an innate component as well as a highly specific adaptive immune system. The innate 
immune system is evolutionarily older and can be found in all animals. In contrast, the 
adaptive immune system is a highly specialized adaptation to the environment and is 
most developed in jawed vertebrates.1 The immune system is able to recognize and 
respond to threats, while not damaging self-structures, and to remember the threat. 
The response to a pathogen can be very powerful and can lead to harmful side effects. 
Hence, a main task of the immune system is to keep the body in a steady state by 
balancing the response to exogenous antigens while maintaining organ function. 
The immune system in the lung is particularly challenged with maintaining 
homeostasis. The alveolar surface, which is important for the gas exchange, is about 
70-140m2 in area. The lungs are filled with 10,000-20,000 liters of ambient air every 
day.2 The inhaled air contains billions of particles, dust, allergens or other harmful 
pathogens. Hence, a network of specialized immune cells is required to clean the 
airways and maintain homeostasis. However, in the case of assault by pathogens, a 
powerful immune response has to be initiated. Among the first line of response are 
innate immune cells. Of these, mononuclear phagocytes (MNPs), which consist of 
macrophages, monocytes, and dendritic cells (DCs), are specialized in the uptake and 
clearance of the antigens. Additionally, the antigens can also be presented by MNPs 
to activate T cells, which are cells of the adaptive immune system. As MNPs line the 
respiratory mucosa, they act as sentinels of the pulmonary immune system and help 
to maintain steady state. 
In the lungs, macrophages are the most abundant innate immune cells and are 
particularly powerful in the uptake of foreign particles. Alveolar macrophages are the 
first cells on the luminal side of the lungs to induce an immune response or to clear 
the particles “silently.” Upon recognition of a pathogen or other danger signals by 
specialized pattern recognition receptors, macrophages release chemical mediators.3 
In case of a pathogen, those mediators can be cytokines to induce inflammation or 
chemokines to attract other immune cells to the site of antigen exposure.4, 5 DCs are 
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another group of MNPs. DCs have specialized in activating naïve T cells.6 For this, 
DCs take up antigen and migrate to the draining lymph nodes, where the antigen is 
presented to naïve T cells. Upon activation, T cells migrate back to the site of infection 
and clear the tissue from the antigen by releasing cytokines or by cytotoxicity mediated 
cell death.7 To date, the knowledge about the innate and adaptive immune system 
has provided curative and preventive therapies. Yet, in the future, humanity will face 
new challenges with antibiotic resistant bacteria, novel emerging viruses and 
tumorous malignancies.8-10 Thus, profound knowledge of immune cells during steady 
state conditions are required. 
Sarcoidosis is a multi-systemic inflammatory disease primarily affecting the lungs that 
is often accompanied by an impaired quality of life. It is characterized by the presence 
of granulomas, which are multinucleated giant cells that contain an antigen on the 
inside to shield the surrounding tissue.11 The etiology of sarcoidosis is still unknown. 
There are indications that sarcoidosis is of infectious origin, but an overreaction of the 
immune system against host structures has also been proposed.12 MNPs are likely 
critical in the initiation of the immune response by encountering the antigen, that leads 
to the subsequent release of granuloma-forming cytokines, and the activation of T 
cells.13 Hence, studying MNPs during steady state can pave the way to better 
understand the pathogenesis of sarcoidosis in order to clear disease and ultimately 
help patients to improve their quality of life. 
This thesis focuses on studying mononuclear phagocytes, in the human respiratory 
tract during steady state and sarcoidosis. It provides an overview of the distribution, 
phenotype, and function of mononuclear phagocytes in healthy and diseased lungs. It 
shows the importance of studying MNPs as they contribute to inflammation in 
sarcoidosis and have a significant value as an outcome predictor. 
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2 AIMS OF THESIS 
The overall aim of this thesis was to map the mononuclear phagocyte network in the 
human respiratory tract to better understand their function in healthy individuals and 
to decipher their importance during sarcoidosis. 
 
The specific aims for the studies were as follows:  
 
• To map the mononuclear phagocyte network in the respiratory tract and in 
blood during steady state (Paper I) and in sarcoidosis patients (Paper II+III), 
 
• To identify unique transcriptional characteristics specific to blood and 
respiratory mononuclear phagocytes in sarcoidosis patients compared to 
steady state conditions (Paper III), 
 
• To study the functional properties of blood and lung mononuclear phagocytes 
during steady state and in sarcoidosis patients (Paper III+IV), 
 
• To investigate whether prevalence or function of mononuclear phagocytes at 
time of diagnosis associate with disease outcome in sarcoidosis patients 
(Paper III). 
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3 MONONUCLEAR PHAGOCYTES  
Mononuclear phagocytes (MNPs) are a group of innate immune cells comprised of 
monocytes, macrophages, and dendritic cells (DCs).14 MNPs surveil tissues for 
potential threats and help maintain homeostasis.15 Common features of MNPs are 
their ability to sense and respond to potentially harmful pathogens by taking up foreign 
substances and producing cytokines.16 Additionally, MNPs are professional antigen-
presenting cells (APCs) that activate T cells in response to foreign antigens.17 Besides 
overlapping features, each of the MNP subsets also have specialized functions.18 In 
recent years, it has become evident that the MNP network is highly heterogeneous 
and its diversity has just started to unravel. Our increasing knowledge about the 
influence of the tissue microenvironment and inflammation on MNPs will improve the 
design of better vaccination strategies and therapeutics.19, 20 
 
3.1 HISTORY OF MONONUCLEAR PHAGOCYTES 
The first detailed knowledge of MNPs dates back to the 19th century.19 Observations 
that splenic cells internalized red blood cells or contained bacilli indicated that 
specialized cells were able to take up particles.20 However, at that time, it was unclear 
whether this was a beneficial process. On the contrary, it was assumed to be a process 
leading to the spread of bacteria.21 Eventually, ground-breaking work by Ilya 
Metchnikov described the existence of cells actively taking up foreign particles, a 
process termed phagocytosis.22 Also, Metchnikov considered phagocytosis a defense 
mechanism of the cells to protect the host. This theory gave rise to the concept of 
cellular innate immunity. Later, all known phagocytosing cells were described as 
constituting the reticuloendothelial system (RES) by Aschoff in 1924.23 Depending on 
the tissue and person describing the phagocytes, up to 30 different names existed for 
similar cells.24 
In the early 20th century, it became evident that macrophages arise from circulating 
monocytes.25, 26 The pioneering work of Robin van Furth in the 1960s and 1970s 
distinguished monocytes and macrophages from polymorphonuclear phagocytes, 
known as granulocytes.27, 28 Van Furth further concluded that tissue macrophages are 
constantly replenished by circulating monocytes that arise from a promonocyte in the 
bone marrow.28 Due to the relationship between monocytes and macrophages and 
their differences to granulocytes, the term mononuclear phagocytes (MNPs) was 
established. In the 1970s, a “dendritic-shaped cell” similar, but with distinct functions, 
from macrophages was identified by Steinman and Cohn and called dendritic cells.29, 
30 Due to their similarity with monocytes and macrophages in morphology, origin and 
function, DCs became part of the MNP system.31 Continued research in the past 
decades has revealed high heterogeneity among MNPs, in particular regarding their 
origin and function. 
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3.2 ONTOGENY OF MONONUCLEAR PHAGOCYTES 
One way to classify MNPs is based on ontogeny - the studies of cellular origin.14 The 
use of mouse models and adoptive transfer of precursor cells into irradiated hosts 
have identified distinct monocyte and DC precursors and deciphered the 
developmental origin of MNPs. 
 
Figure 1. Hematopoiesis and development of MNPs. A simplified model with focus on the 
origin of MNPs. Hematopoietic stem cells (HSCs) differentiate into multipotent precursors 
(MPPs). MPPs give either rise to common lymphoid progenitors (CLPs) or monocyte/ 
macrophage–DC progenitors (MDPs). CLPs develop into pre-pDC precursors that can also 
arise from common DC precursors (CDPs), which develop from MDPs. Pre-pDCs give rise 
to pDCs. CDPs develop into pre-cDCs and finally to cDC1s and cDC2s. Classical monocytes 
(CMs) arise from common monocyte precursors (cMoPs) that develop from MDPs. In blood, 
CMs differentiate into intermediate monocytes (IMs) and non-classical monocytes (NCMs). 
CMs extravasate to become tissue monocytes or differentiate into monocyte-derived DCs 
(mo-DCs) or macrophages (mo-Macs). Tissue-resident macrophages are also seeded by 
independent precursors during embryogenesis from yolk sac (YS) macrophages or from 
fetal liver (FL) monocytes.  
 
Historically, DCs and particularly macrophages were thought to be descendants of 
highly plastic monocytes. However, recent advances using lineage tracing, single-cell 
technologies, and cellular barcoding have identified individual precursors of the 
monocyte, DC, and macrophage cell lineages.32 A major paradigm shift brough about 
by advanced technologies was the elucidation of the origin of tissue macrophages.33 
For decades, it was believed that monocytes differentiate into macrophages upon 
entering the tissue. This knowledge was challenged by the discovery of independent 
macrophage development from precursors in the embryonic yolk sac or the fetal liver. 
The distinct origin of tissue-resident macrophages has been shown for a variety of 
organs including the skin, brain, liver, and lungs.34-37 
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In detail, as illustrated in Figure 1, hematopoietic stem cells (HSCs) give rise to 
multipotent precursors (MPPs) followed by the common myeloid precursors (CMPs). 
In both mouse and human, DCs and monocytes diverge at the stage of the 
monocyte/macrophage–DC progenitors (MDPs) developing into the common DC 
precursors (CDPs) and the common monocyte precursors (cMoPs).38-43 The cMoPs 
give rise to monocytes in the presence of colony stimulating factor 1 (CSF1).44 Tissue-
resident macrophages derive from several sources. During development, 
macrophages are seeded from the yolk sac as well as the fetal liver while in adults, 
macrophages either self-renew or differentiate from extravasated monocytes.34 
Crucial for the development of DCs is the expression of the Fms-like tyrosine kinase 
3 (FLT3) and the presence of the growth factor FLT3 ligand.45 From CDPs, pre-
conventional DCs (pre-cDCs) and pre-plasmacytoid DCs (pre-pDCs) progenitors 
develop.39 There is evidence that the two cDC subsets, characterized by expression 
of the transcription factors IRF8 and IRF4 and termed cDC1s and cDC2s, respectively, 
derive from distinct pre-cDC precursors.46-48 pDCs develop from the pre-pDC 
precursors relying on the transcription factors E2-2 and ZEB2 for development.49, 50 
However, the precursor of pDCs is currently debated as it has also been shown that 
pDCs can develop from common lymphocyte progenitors (CLPs).51 This suggests that 
pDCs may be of lymphoid origin in contrast to cDCs and monocytes, which are of 
myeloid origin. 
 
3.3 MONONUCLEAR PHAGOCYTE SUBSETS 
The MNP network in vivo is highly complex and our understanding of MNP subsets as 
well as their function is constantly updated. Importantly, most data were generated in 
animal models and translation into the human system has to be interpreted carefully. 
It has become obvious that relying merely on surface epitopes was not suitable for the 
comparison of MNP subsets between mice and humans or when comparing different 
tissues.52 Also, monocytes are highly plastic and can acquire a macrophage or DC-
like phenotype upon entering tissues, and can thereby share many surface epitopes 
with bona fide DCs and tissue-resident macrophages.53 Hence, identification of 
transcription factors and transcriptomic signatures specific to MNP subsets were 
needed. Unbiased mass cytometry and single-cell technologies identified gene 
signatures specific to MNP subsets and their successors and allowed the careful 
mapping of MNP heterogeneity in tissues at steady state and during inflammation.54-
57 Common to identifying all MNP subsets is their surface expression of the human 
leukocyte antigen DR (HLA-DR). HLA-DR is expressed by all APCs including B cells. 
In human blood, three different monocytes can be distinguished by their expression of 
CD14 and CD16.58 Further pDCs can be further identified by the expression of the IL-
3 receptor (CD123) as well as cDC1s and cDC2s by their expression of CD141 and 
CD1c, respectively (Figure 2A).59  
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MNPs are equipped with tools to degrade external antigens. Macrophages have 
herein specialized compared to monocytes and DCs.60, 61 A further common feature 
to all MNPs is their expression of pattern recognition receptors (PRRs) that sense the 
foreign materials and subsequently lead to the production of cytokines.53, 62, 63 
Monocytes, in particular, express a wide range of PRRs, which allows them to respond 
rapidly and effectively upon encounter of an antigen.64 Finally, MNPs have the ability 
to activate T cells by loading antigenic peptides on MHC class I and II molecules and 
presenting them to cognate T cell receptors. Among MNPs, DCs have specialized in 
activating naïve T cells, which takes place in the draining lymph nodes. DC upregulate 
receptors that mediate migration to the lymph node upon encounter of an antigen.65, 
66 After arrival in the lymph node, DCs have matured by upregulation of co-stimulatory 
receptors and subsequently instruct naïve T cells.16 Besides their overlapping 
functions, each individual MNP subset has also distinct functional features (Figure 
2B). Together, MNPs help maintain homeostasis and respond effectively to potential 
threats. A summary of surface epitopes and specialized tasks of MNP subsets is 
summarized in Table 1. 
 
Figure 2. Mononuclear phagocyte subsets and common functions. (A) Human 
mononuclear phagocytes consist of DC and monocyte subsets as well as macrophages. (B) 
Common functions shared by all MNPs. (I) The uptake of foreign antigens (phagocytosis), 
(II) the recognition by PRRs and degradation of antigens. MNPs respond to PRR activation 
by (III) secretion of cytokines and (IV) presentation of antigens on MHC molecules to T cells. 
 
3.3.1 Monocytes and macrophages  
The role of monocytes has for a long time focused on their ability to differentiate into 
tissue-resident macrophages or monocyte-derived DCs. Only recently, the importance 
of monocytes as an individual MNP subset was acknowledged with their role as first 
responders to inflammation.67 Monocytes respond rapidly by producing 
proinflammatory cytokines upon stimulation.68 They account for about 10 % of 
circulating leukocytes and have a high turnover rate.69 In the bone marrow (BM), 
cMoPs are highly proliferative and post-mitotic monocytes are retained creating a pool 
of monocytes.70 During inflammatory conditions, BM monocytes are released and 
migrate quickly to the site of inflammation.71-73 In humans, three monocyte subsets 
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have been identified in circulation: classical monocytes (CMs), intermediate 
monocytes (IMs), and non-classical monocytes (NCMs).18 Monocytes are 
characterized by their expression of the lipopolysaccharide (LPS) co-receptor (CD14) 
and the Fc-gamma receptor III (CD16). CMs are CD14+CD16-, IMs express high levels 
of both CD14 and CD16, and NCMs are CD14 low and CD16+. This differential 
expression of identifying markers already indicates the developmental progress from 
CMs to IMs and NCMs. In the BM, only CMs develop from the cMoPs and express 
high levels of CCR2, a chemokine receptor critical for egress from the BM.74 Once 
released into the circulation, CMs remain in circulation for about one day.70 About 1% 
of CMs differentiate into IMs while 99% of CMs extravasate into the tissues.70 CCR2 
is believed to also mediate extravasation of CMs. As IMs express CCR2 at lower levels 
compared to CMs, IMs remain in circulation and ultimately differentiate into NCMs with 
an average half-life time of seven days (Figure 1).70, 75 
A clear distinction between the monocyte subsets is difficult as the differentiation from 
CMs to IMs and NCMs is smooth and characterized by the up- and downregulation of 
cell surface receptors.75 Another challenge in the study of monocytes is that an 
intermediate population is missing in mice, where monocytes are characterized based 
on their expression of Ly6C.76 Functionally, monocytes are potent in producing both 
pro- and anti-inflammatory cytokines.68 This feature is mostly attributed to classical 
and intermediate monocytes, although NCMs were also shown to produce pro-
inflammatory tumor necrosis factor (TNF) upon encountering viruses.77 Additionally, 
NCMs are potent in maintaining epithelial cell integrity during atherosclerosis.78 
Upon extravasation, monocytes are exposed to the local cytokine environment that 
differs between steady state and inflammation. Due to their plasticity, monocytes 
acquire a phenotype based on the cytokine milieu. A fraction of monocytes remain as 
tissue monocytes and are distinct from monocyte-derived DCs (mo-DCs) and 
monocyte-derived macrophages (mo-Macs).53 
In 2000, the model of M1 and M2 macrophages was introduced as an approach to 
describe pro- and anti-inflammatory macrophages.79 However, in recent years it has 
become more obvious that the heterogeneity and dynamics of macrophages cannot 
be explained with the simple M1/M2 dichotomy. Extensive research on tissue-resident 
macrophages has led to the characterization of key points that shape macrophage 
identity.80 First, the origin is a key factor distinguishing macrophages seeded during 
embryogenesis versus mo-Macs. During steady state, tissue-resident macrophages 
arise from three waves to seed various tissues: first, from the yolk sac followed by fetal 
liver monocytes, and during adulthood from circulating monocytes.33, 35-37, 80-82 Second, 
their location and time spent within a tissue is of importance as proposed in the niche 
theory.34, 83 Within each tissue, macrophages are engrafted in niches formed by tissue 
epithelial cells that produce growth factors required for macrophage identity. The 
phenotype and function of macrophages are dependent on the local environment, 
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which can also differ between niches in one organ. Finally, inflammation shapes and 
influences macrophages.84 During steady state and inflammation, macrophages 
continuously undergo cell death as well as self-renewal.85-90 Empty niches due to 
infection or inflammation are preliminarily filled with recruited monocytes that mimic 
the function of tissue-resident macrophages before replenished with tissue-resident 
macrophages. Altogether, the macrophage compartment is very heterogeneous, and 
macrophages should cautiously be described in their respective tissue and 
inflammatory context. 
 
3.3.2 Dendritic cells  
DCs are often described as the cells that bridge the innate and adaptive immune 
systems, particularly as they are the most potent cell subset at activating naïve T 
cells.91-93 Human DCs can broadly be divided into three distinct populations: 
plasmacytoid DCs (pDCs) and two myeloid or conventional DCs (cDCs). The 
expression of surface markers on DCs in human and mice differ vastly.32 Hence, it 
was difficult for a long time to translate findings across species. In a recent study 
however, common surface epitopes and transcription factors were describe to reliably 
identify pDCs and cDCs across species and tissues.54 Furthermore, recent advances 
using single-cell technologies have identified further non-canonical DC subsets 
suggesting more heterogeneity already at steady state.94-96 
pDCs, identified based on the expression of the IL-3 receptor (CD123), are most 
commonly found in circulation and lymphoid tissue.97-99 pDCs have high expression of 
Toll like receptors (TLRs) 7 and 9, which sense viral single-stranded RNA and double-
stranded DNA, respectively.100 Upon TLR activation, pDCs release high amounts of 
antiviral interferon alpha (IFNα).100, 101 Despite their potent antiviral activity, pDCs are 
poor T cell activators.102, 103 These observations in context with the debated myeloid 
or lymphoid progenitor of pDCs has led to the assumption that pDCs may be 
contaminated with cDC precursors resulting in one innate lymphoid population and 
one cDC precursor population.51, 94, 95 
In human blood, cDC1s represent only a small fraction of DCs (about 1/10 of cDC2s) 
and are characterized by the expression of CD141.59 As CD141 is also expressed by 
other cells in tissue, using X-C motif chemokine receptor 1 (XCR1) or the transcription 
factor interferon regulatory factor 8 (IRF8) were shown to be useful to reliably identify 
cDC1s.54, 104 However, using transcription factor staining is not always possible, such 
as in experiments using fluorescence-activated cell sorting (FACS) and subsequent 
functional experiments. Functionally, cDC1s were shown to be superior in cross-
presentation, a process characterized by the uptake of apoptotic cells and 
presentation of antigen peptides to CD8+ T cells.105-107 However, these data could not 
be confirmed in humans as cDC2s and mo-DCs also cross-present antigen to CD8+ 
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T cells.108-111 Furthermore, cDC1s were better at mediating Th1 responses compared 
to cDC2s by high expression of IL-12.105, 107 In humans, CD4+ T cell activation is less 
restricted to cDC1s as cDC2s and mo-DCs were also shown to be potent Th1 
inducers.112, 113 
 
Figure 3. Overview of T cell activation by dendritic cells. Allergens or pathogens are 
inhaled and cross the epithelium where they are taken up by MNPs, such as DCs. DCs 
recognize antigenic structures and mature by upregulating co-stimulatory molecules and 
CCR7, which mediates trafficking to the draining lymph nodes. In the lymph nodes, DCs 
present the antigen on MHC I or MHC II to CD8+ cytotoxic T lymphocytes (CTL), also called 
cross-presentation, and CD4+ T cells, respectively. Depending on the cytokine signals by 
the DCs, CD4+ T cells differentiate into specific T helper cell (Th) subsets. 
 
The most frequent myeloid DC subset in human blood are cDC2s. cDC2s are 
characterized by their expression of CD1c.59 CD1c is also expressed by mo-DCs in 
tissues.55, 114-116 Hence, further markers such as SIRPα (CD172) or the transcription 
factor interferon regulatory factor 4 (IRF4) are used to specifically identify cDC2s.6, 54 
In comparison to cDC1s, cDC2s express a broader variety of TLRs, which improves 
their capability to sense foreign antigens.117 cDC2s were shown to activate naïve T 
cells and skew them towards Th1, Th2, Th17 as well as regulatory T cells (Tregs) by 
secreting a variety of cytokines including TNF, IL-1β, IL-10 and IL-23.113, 118-120 This 
diversity in potential cytokine responses suggests a heterogeneity in cDC2s. The 
migration of cDC2s to the lymph node is mediated by CCR7, CCL19, and CCL21.121, 
122 The upregulation of CCR7 as well as co-stimulatory molecules CD80 and CD86 
are together called maturation. Upon arrival in the lymph node, DCs have processed 
the antigen and loaded on MHC class I and II molecules to activate naïve CD8+ and 
CD4+ T cells, respectively (Figure 3). 
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3.3.3 Monocyte-derived cells 
Monocyte-derived macrophages (mo-Macs) or dendritic cells (mo-DCs) were for a 
long time used as a model to study the function of macrophages and DCs in vitro. 
Using monocytes from the blood and adding M-CSF or GM-CSF leads to the 
differentiation into mo-Macs,123, 124 while GM-CSF and IL-4 generates mo-DCs.125 
Those in vitro model systems are helpful to study the basic functions of mo-Macs and 
mo-DCs as high numbers of cells can be generated in a short time. However, with the 
advanced knowledge of MNP origin, it has become obvious that in vitro-generated 
monocyte-derived cells are also scrutinized as they are not a reflection of bona fide 
DCs or tissue-resident macrophages.126 
Table 1. Characteristics of human mononuclear phagocytes.54, 55, 114, 115, 127-129 
 
However, monocyte-derived cells have also been found in vivo, primarily contributing 
to inflammatory conditions through their production of TNF, IL-6 or IL-1β.116 Depending 
on the observations, these cells were named inflammatory monocytes/DCs116 or 
TipDCs130 in human and mouse inflammation models, respectively. However, human 
mo-DCs also develop during steady state upon entering tissues and are characterized 
by their common expression of monocyte and DC markers such as CD14 and CD1c, 
respectively.55, 114, 115, 128, 129, 131-133 Additionally, mo-DCs express HLA-DR and CD11c 
together with the tissue-specific mannose receptor (CD206) but lack the macrophage 
specific marker CD163.111, 114, 115 Besides their rapid recruitment to the site of 
inflammation and production of pro-inflammatory cytokines, mo-DCs were also shown 
to activate CD4+ and CD8+ T cells.116, 133 Upon activation, mo-DCs also secrete IL-23, 
a potent cytokine that induces Th17 polarization. These observations derive from 
Human MNPs cDC1 cDC2 Monocytes 
Macro-
phages 
mo-DCs 
Phenotype 
CD141, 
XCR1, 
CLEC9A, 
IRF8 
CD1c, 
CD172a, 
IRF4 
CD14, CD16, 
CCR2 
CD11b, 
CD16, 
CD206, 
CD163 
CD14,  
CD1a-c, 
CD172a, 
CD206 
Cytokines 
produced 
TNF, IL-6,  
IL-12 
TNF, IL-1β, 
IL-6, IL-12, 
TGF-β, IL-23 
TNF, IL-6, IL-
12, IL-10, 
TGF-β 
TNF, IL-1β, 
IL-6, TGF-β 
TNF, IL-1β, 
IL-6, IL-12, 
IL-23 
T cell activation 
CD4       
(Th1) 
CD8 
CD4       
(Th2, Th17) 
CD8 
- - CD4       
(Th1, Th17) 
CD8 
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ascites and rheumatoid arthritis models with pathogenic Th17 cell involvement (Table 
1).116, 133 Hence, mo-DCs may contribute to disease severity during inflammatory 
disease. 
In conclusion, comparative analysis of mice and humans have characterized DCs, 
monocytes, and macrophages with distinct cell surface and transcription factor 
expression allowing for the comparison of MNPs across species. However, the 
challenge remains to map in detail the distribution and function of human MNPs in 
different tissues.  
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4 THE RESPIRATORY SYSTEM 
The respiratory system is divided into an upper (nasal cavity, pharynx, and larynx) and 
lower respiratory tract (trachea, bronchi, and lungs). In contrast to mice, sampling the 
human lower respiratory tract is challenging and often an invasive procedure. Studying 
pulmonary immune cells is often accompanied by caveats. 
 
4.1 SAMPLING THE RESPIRATORY TRACT 
Surgical lung resections are often performed on patients with lung cancer or 
pulmonary fibrosis.134 In order to compare immune cell composition and function, often 
cells from the affected (disease) and non-affected (control) regions of the lungs are 
obtained. However, it is unclear to what extent an unaffected area from a patient with 
pulmonary disease resembles the lung tissue of a healthy individual. Often an ongoing 
inflammation alters neighboring areas of the organ thereby also affecting immune 
cells.83 Additionally, excised tissue contains blood vessels with circulating immune 
cells that could be confused with tissue-resident cells.115 As an advantage of surgical 
resections, samples from the lymph nodes draining the diseased and non-diseased 
areas of the lungs can often be obtained.135 
Bronchoscopy is another invasive but safe and well-tolerated method to sample the 
respiratory tract. An overview of the sampling sites feasible by bronchoscopy is 
illustrated in Figure 4. A fiberoptic bronchoscope allows for the visualization and 
sampling of the mucosal surfaces of the trachea, bronchi, and alveoli.136 During a 
bronchoscopy, several methods sample the lower airways. From proximal to distal: 
collection of endobronchial biopsies (EBB), bronchial brush (BB), bronchial wash 
(BW), as well as bronchoalveolar lavage (BAL).114, 137 While EBBs collect bronchial 
tissue specimen, lavages are performed with a saline solution that collects cells lining 
the mucosal surface. To what extent cells collected by lavages reflect lung tissue is 
currently debated.138, 139 An advantage of the lavages is the subsequent minimal 
manipulation of cells as compared to enzymatic digestion of bronchial tissue 
specimens obtained by EBBs. Enzymatic treatment can cleave surface proteins that 
are required for the identification or phenotyping of immune cells.140, 141 Also, tissue 
digestion often requires incubation at 37°C for optimal enzyme function, which 
metabolically affects cells. During a bronchoscopy, also the mediastinal and hilar 
lymph nodes can be sampled using endobronchial ultrasound-guided transbronchial 
needle aspiration (EBUS-TBNA).142 In the clinical diagnostics, EBUS-TBNA has 
proven useful as an on-site diagnostics exam.143 Sampling healthy volunteers, 
however, is difficult as only inflamed lymph nodes are usually large enough for optimal 
sampling. 
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Figure 4. The lower respiratory tract and sampling sites used in this thesis. The lower 
respiratory tract consists of trachea, bronchi and the lung parenchyma. Bronchoscopies 
were performed to sample the different sites of the lower respiratory tract. EBUS-TBNA: 
endobronchial ultrasound-guided transbronchial needle aspiration. 
 
Another factor to consider when processing samples for research is time. After 
retrieval of the tissue samples, it is critical to provide low temperatures to not induce 
metabolic changes in the cells that would result in the up- or downregulation of 
proteins. Depending on the research question, samples can either be processed and 
used for experiments immediately or cells frozen for use at a later date. However, one 
cycle of freeze-thawing can also have effects on cell functionality and surface protein 
expression.114 Hence, it is important to employ consistent strategies within a project. 
In conclusion, sampling the human respiratory tract is often difficult, and this has 
limited our knowledge on the immune system in this compartment. Hence, studies 
sampling different anatomical sites of the respiratory tract side-by-side are needed. 
This will improve our understanding on how immune cells are distributed and function 
along the respiratory tract, and in comparison, to their well-known blood counterparts. 
 
4.2 PULMONARY MONONUCLEAR PHAGOCYTES 
Lung diseases are one of the leading causes of deaths in the world.144 Often the 
immune system can handle short-term exposure to noxious particles, but long-term 
exposure may lead to irreversible changes, including fibrosis.145 Common pulmonary 
diseases include tumorous malignancies, infections (e.g. tuberculosis), chronic 
obstructive pulmonary disease (COPD), asthma and, less frequently, interstitial 
diseases (e.g. idiopathic pulmonary fibrosis, sarcoidosis). In order to better understand 
the contribution of MNPs to disease pathogenesis, their role during healthy steady 
state conditions has to be investigated. 
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During the past years, we and others have used different approaches to map human 
MNPs from the respiratory tract during steady state.114, 115, 129 MNPs from lavages, 
bronchial biopsies, as well as lung tissues and their draining lymph nodes from 
deceased donors showed the presence of macrophages, monocytes, and DCs. The 
frequency of the MNP subsets varied between the studies due to the strategy used to 
define them.114, 115, 129 Interestingly, most pronounced differences in cell composition 
were observed between blood and the respiratory tract. A shift towards intermediate 
monocytes, increased percentage of cDC1s and very few pDCs were observed in the 
lungs compared to blood.114 
Functionally, pulmonary MNPs differ in their abilities to respond to challenges. For 
example, while all MNPs have been shown to phagocytose bacterial particles, 
macrophages and monocytes especially excel at this.129 Furthermore, monocytes 
potently produce TNF upon TLR stimulation, while DCs were better in activating 
allogeneic T cells than monocytes.114, 115 These data highlight the heterogeneity of 
MNPs within the respiratory compartment and a distinct division of labor between the 
subsets in maintaining homeostasis. 
While the role of MNPs during pulmonary inflammation and infection has been studied 
for many years, observations have often contradicted each other or have been 
inconclusive. This has likely been due to the strategy to identify MNPs and a small 
sample size.146 Among the most common particles that the pulmonary innate immune 
system has to tackle are caused by cigarette smoke. Smoking is a risk factor for 
several pulmonary diseases such as COPD or lung cancer.147, 148 Alveolar 
macrophages are affected by smoking by increasing cell numbers and altered 
functions.149-153 The constant exposure to cigarette smoke also leads to persistent 
inflammation in the lungs affecting other MNP subsets. DCs accumulate and are more 
mature in the lungs of COPD patients compared to healthy controls.154 However, there 
are also reports implying that smoking COPD patients that have less mature or 
tolerogenic DCs compared to smokers without COPD, which may be caused by 
different isolation and analysis methods.155, 156 
In general, studies with patients suffering from pulmonary diseases often show a 
heterogenous picture. Patients may wait months or years before seeking health care 
and present at the clinic at different stages of the disease. Consequently, analysis of 
immune parameters at that time may only be a snapshot of the disease. Thus, a 
careful clinical characterization accompanied by a close follow up of patients 
longitudinally is needed to better understand immune mechanisms involved during the 
disease course.  
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5 SARCOIDOSIS 
Sarcoidosis is a systemic inflammatory disease characterized by the formation of non-
caseating granulomas in affected organs. Granulomas can occur in the skin, eyes, 
heart, and the central nervous system, but the most commonly affected organs are 
the lungs and the lung-draining lymph nodes.11, 157 As granulomas can form in multiple 
organs, patients often present with a multitude of different clinical symptoms. It has 
been estimated that 30-40% of patients usually recover from sarcoidosis within two 
years and 80% recover within five years.158-161 However, 20% develop chronic 
progressive disease that ultimately leads to fibrosis and organ failure.162 The clinical 
phenotype is likely determined by genetics and influenced by the environment, 
however, these factors do not fully explain sarcoidosis pathogenesis.163 Therefore, 
studying the underlying immunological mechanisms is a central aspect of sarcoidosis 
research to better understand which factors determine the course of the disease. 
 
5.1 EPIDEMIOLOGY AND CLINICAL CHARACTERISTICS 
Sarcoidosis has been reported around the world but with differences based on the 
geographical region and ethnicity.164 The highest incidence and prevalence of 
sarcoidosis are found in the Scandinavian countries and among African Americans.159, 
164-166 In Sweden, the incidence is 11.5 per 100,000 individuals per year, which equals 
to about 1200 new cases each year.167 Sarcoidosis can affect both men and 
women.164 The epidemiological data indicate differences in the onset of sarcoidosis. 
In men, the highest incidence is between 30 and 50 years of age, whereas women 
have the highest incidence rates between the age of 30-40 and a second peak 
between 50 to 60 years.167 
 
Figure 5. Organ involvement in sarcoidosis. Shown are the most common tissues 
affected by granuloma formation. Percentages show the prevalence of organ involvement. 
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The diagnosis of sarcoidosis is based on findings of non-caseating epithelioid cell 
granulomas in affected organs. Malignancies, infections and other granuloma-causing 
antigens should be excluded prior to sarcoidosis diagnosis.168 The range of clinical 
symptoms depends mostly on the organs involved (Figure 5).11 A common, not organ-
specific symptom is fatigue, which greatly affects the quality of life in patients.169 In 
pulmonary sarcoidosis, organ-specific symptoms include dry cough or shortness of 
breath.11 Intrathoracic lymph node enlargement and parenchymal infiltrates can be 
detected using radiographic tools like conventional X-ray and computed tomography 
scan (Table 2).170, 171 To detect granulomas, patients undergo a bronchoscopy to 
sample biopsies from the bronchial mucosa. Additionally, lung parenchyma specimen 
can be obtained by transbronchial lung biopsies, and EBUS-TBNA can sample the 
lung-draining lymph nodes.172 Additionally, a lavage of the lower airways is commonly 
performed to collect the bronchoalveolar lavage (BAL) fluid of the lower airways in 
order to retrieve the cells lining the bronchial mucosa and alveoli. Among BAL cells, 
an elevated ratio (>3.5) of CD4+ to CD8+ T cells serves as a diagnostic tool.173 
Table 2. Chest radiographic staging according to Scadding.172 
Chest radiography stage Characteristics 
0 No alterations 
I Bilateral hilar lymphadenopathy 
II Bilateral hilar lymphadenopathy 
with pulmonary infiltrates 
III Pulmonary infiltrates only 
IV Fibrosis, volume reduction 
 
One third of sarcoidosis patients in Sweden present with an acute disease onset 
characterized by fever, enlarged bilateral hilar lymph nodes, erythema nodosum 
and/or periarticular inflammation.174 This syndrome was first described by the Swedish 
physician Sven Löfgren in 1946 and later termed Löfgren’s syndrome (LS).175 About 
76% of LS sarcoidosis patients resolve the disease within two years.161 Most LS 
patients express the human leukocyte antigen (HLA)-DR with the subtype B1*03. In 
this cohort of patients, a spontaneous remission was observed in >95% of the cases 
implying a genetic and immune component contributing to disease outcome.160, 161, 176 
Hence, LS patients usually have a better prognosis compared to non-LS patients. 
Besides genetics, also immune cells may also play a role in the pathogenesis and 
resolution of LS and non-LS sarcoidosis. 
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Treatment of sarcoidosis focuses on relieving symptoms and preventing irreversible 
sequelae. No drug has been convincingly proven to change the disease course and 
outcome. Corticosteroids are the primary choice of medication in sarcoidosis patients. 
It can be combined with immunosuppressive drugs such as methotrexate and 
azathioprine as a second line treatment.177 In refractory cases with progressive 
disease, anti-inflammatory biological drugs such as tumor necrosis factor (TNF) 
inhibitors may be used as a third line treatment.178 However, studying the underlying 
immunological mechanisms that contribute to pathogenesis may identify patients in 
need of treatment early on.  
 
5.2 ETIOLOGY AND PATHOGENESIS 
Pulmonary sarcoidosis is characterized as a T cell-driven disease due to the high 
number of T cells accumulating in the lungs, particularly around the granulomas. The 
granuloma-causing antigen(s) have not yet been identified. The innate immune 
system, however, mounts an immune response against the antigen by release of pro-
inflammatory cytokines and T cell activation. In the following section, details about the 
current understanding of the causative antigen as well as the immune response will 
be discussed. 
 
5.2.1 The granuloma 
Granulomatous structures, as formed by infection (e.g. tuberculosis) or as a response 
to foreign particles (e.g. beryllium), constitute a defense mechanism by the immune 
system to protect the tissue.179 In general, the core of a granuloma consists of 
macrophages or epithelioid giant cells that have phagocytosed an antigen.13 
Depending on the antigen, macrophages release pro-inflammatory cytokines to 
eliminate the antigen and to recruit additional phagocytes. In sarcoidosis, it is 
hypothesized that the immediate response fails to clear the antigen. When the 
inflammation persists, macrophages aggregate and divide incompletely, forming 
multinucleated giant cells.180 This process is mediated by the mTOR pathway.181 The 
aggregation of macrophages is called a granuloma and can differ based on the 
antigen. In contrast to tuberculosis granulomas where bacteria induce necrosis in 
macrophages, sarcoid granulomas are non-necrotizing, indicating an agent with no 
mycobacterial background.182, 183 
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5.2.2 The quest for the antigen 
The search for the sarcoidosis-inducing antigen has been ongoing for decades. 
However, a common antigen found in all sarcoidosis patients is still lacking. Several 
agents have been proposed. Bacterial DNA and proteins from Mycobacteria spp and 
Cutibacteria spp were detected in the granulomas of a cohort of sarcoidosis 
patients.184 Additionally, T cells challenged with mycobacterial antigens such as the 6 
kDa early secretory antigenic target (ESAT-6) or mycobacterial catalase-peroxidase 
(mKatG) showed enhanced activation and cytokine release, suggesting previous 
encounter.185-187 Furthermore, immune responses were also detected after stimulation 
with self-antigens against vimentin, particularly in HLA-DRB1*03-positive LS 
patients.188 Also, within the granulomas high levels of serum amyloid A (SAA) were 
found. SAA is an acute phase protein and is elevated during sarcoidosis. In contrast 
to other proposed antigens, SAA is likely not the causative agent but misfolded and 
aggregated protein stimulates TLR2 in macrophages.189 Constant TLR2 stimulation 
leads to the activation of the nuclear factor kappa-light-chain-enhancer of activated B 
cells (NF-κB) pathway and release of proinflammatory cytokines that promote 
granuloma formation. 
It is also possible that genetic factors influence the formation of granulomas in 
sarcoidosis. As mentioned above, the HLA-DRB1*03 haplotype is commonly found in 
patients with Löfgren’s syndrome. Furthermore, a clonal expansion of T cells with the 
variable alpha chain 2.3 of the T cell receptor (TRAV2.3) was identified in BAL of 
particularly LS patients.190, 191 Increased number of TRAV2.3-expressing T cells 
associates with good prognosis.192 This suggests the presence of a specific antigen 
being presented by a certain HLA molecule that is recognized by T cells expressing 
the specific T cell receptor TRAV2.3. 
The search for the antigen(s) causing sarcoidosis continues as none of the above 
candidate agents were causative in all patients. It is also speculated that LS and non-
LS sarcoidosis are separate disease entities caused by different agents.12 
 
5.2.3 T cells in sarcoidosis  
Patients with pulmonary sarcoidosis have an expansion of particularly CD4+ T cells.173 
Activated T cells show mostly a T helper cell 1 (Th1) phenotype due to release of high 
levels of interferon gamma (IFNγ) after stimulation with candidate antigens in vitro.193-
195 Most T cells obtained from BAL expressed the transcription factor Tbet, which is 
specific for the Th1 lineage. The Th1 dogma was later challenged as also other 
cytokines such as IL-17 were found in the BAL fluid of sarcoidosis patients suggesting 
Th17 involvement.196-200 T cells were also found to co-express Tbet and RORγt, the 
transcription factor for Th17 cells, suggesting plasticity in the T cell compartment.197 
The percentage of Tbet+RORγt+ cells was particularly high in BAL T cells from LS 
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patients compared to non-LS patients. T cells from LS patients also expressed higher 
levels of IL-17, which may influence the better outcome of LS patients compared to 
non-LS patients.197 In contrast, another study identified CXCR3+CCR6+ T cells in BAL 
of sarcoidosis patients. Both are chemokine receptors specific to Th1 and Th17 cells, 
respectively. This T cell subset was termed Th17.1 cells.198 Th17.1 cells were more 
abundant than Th1 cells in sarcoidosis patients and potently produced IFNγ upon 
stimulation.198 From a clinical perspective, Th17.1 cells were expanded in BAL and 
lymph nodes of sarcoidosis patients and increased numbers correlated with 
progressive disease development.199 These results contradict each other to some 
extent as RORγt+ cells were expanded in LS patients, which usually resolve disease 
within two years, while Th17.1 cells were instead predicting disease progression.200 
An overview of T cells involved in sarcoidosis is shown in Figure 6. A combination of 
transcription factor, chemokine receptor, and cytokine staining in one panel could 
possibly help to identify the small but important differences between T cell subsets. 
 
Figure 6. The phenotype of T cells in sarcoidosis. In sarcoidosis, naïve T cells become 
activated by DCs and differentiate mostly into Th1 or Th17.1 cells. Th17.1 cells are 
characterized by their expression of Tbet and RORγt and their chemokine receptors CCR6 
and CXCR3. Th17.1 cells potently produce IFNγ and tor some extent IL-17. Despite their 
expansion in patients with chronic sarcoidosis, Th17.1 cells are also found in high numbers 
in LS patients that usually have a good prognosis. 
 
These data highlight the heterogeneity of T cells in LS and non-LS sarcoidosis. Thus, 
it is important to understand how professional antigen-presenting cells (APCs) activate 
and skew the T cell response. That knowledge may help to target and manipulate 
APCs therapeutically in order to improve the resolution of the disease. 
 
5.2.4 Mononuclear phagocytes in sarcoidosis 
Alveolar macrophages (AMs) in sarcoidosis are well studied due to their abundance 
in the airways and their easy retrieval with BAL. AMs make up 95% of BAL cells in 
healthy controls and about 70-80% in sarcoidosis patients.201, 202 AMs are potent in 
phagocytosing foreign particles and recognize antigenic structures with a specialized 
set of pattern recognition receptors.114, 129 Upon recognition, AMs secrete soluble 
mediators to induce inflammation and to recruit cells to the site of antigen encounter. 
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In sarcoidosis, AMs are potent producers of TNF, IL-1β and IL-6 compared to 
macrophages from healthy controls upon stimulation with the TLR2 ligands and 
microbial candidate antigens ESAT-6, mKatG or SAA.186, 189, 203 The role of AMs in 
activating T cells is less well studied. Early reports suggested that AMs from 
sarcoidosis patients are better at activating autologous T cells compared to 
macrophages from healthy controls.204, 205  
A special role in sarcoidosis is attributed to TNF. AMs from sarcoidosis patients 
produce TNF intrinsically without stimulation.206-208 TNF is important in forming and 
maintaining the sarcoid granulomas and high TNF production associates with disease 
severity in sarcoidosis.209 Further, anti-TNF treatment was shown to be beneficial for 
sarcoidosis patients by improving their lung function or having less infiltrates on the 
chest x-ray.178, 210-213 These data suggest that AMs in sarcoidosis are highly activated 
and contribute to inflammation, granuloma formation and maintenance as well as T 
cell activation. 
Less well studied in sarcoidosis are pulmonary monocytes and monocyte-derived cells 
due to their resemblance to macrophages. We have recently described how MNPs, 
including pulmonary monocytes, are distributed in the respiratory tract and the lung-
draining lymph nodes (LLN) of LS and non-LS sarcoidosis patients.214 In blood, the 
frequencies of intermediate monocytes have been shown to be expanded in 
sarcoidosis patients, likely as a response to the systemic inflammation.215-217 
Functionally, monocytes produced less IL-10 upon stimulation compared to controls 
and induced fewer suppressive T cells.218 Further studies have shown that blood 
monocytes were potent producers of TNF and IL-6 upon stimulation compared with 
controls, which could be due to higher expression of TLRs in sarcoidosis 
monocytes.203, 215 Furthermore, monocytes from sarcoidosis patients also produced 
more IL-1β upon LPS stimulation, indicating activation of the NLRP3 inflammasome 
pathway that may be involved in granuloma formation.219 Collectively, these studies 
indicate a pro-inflammatory phenotype for circulatory monocytes in sarcoidosis. 
Dendritic cells (DCs) may play a crucial role in sarcoidosis as the superior subset to 
activate T cells. However, recent reports were inconclusive about the contribution of 
DCs to pathogenesis in sarcoidosis Overall, frequencies and numbers of DCs were 
unchanged or only slightly increased in blood and BAL of sarcoidosis patients 
compared to healthy controls.220, 221 DCs found surrounding granulomas were mature 
as assessed by CD86 expression.221 In a different report, BAL DCs were less mature 
compared to controls as assessed by CD1a expression.220 This heterogeneity in 
distribution and maturation was also reflected in their capacity to induce T cell 
proliferation. Allogeneic T cells proliferated after co-culture with BAL DCs from 
sarcoidosis patients similarly to that of controls.221 Using mo-DCs from blood and 
magnetic bead isolated blood DCs, on the other hand, induced less T cell proliferation, 
suggesting anergy of DCs from sarcoidosis patients.222, 223 The heterogeneity of these 
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results may be due to the differences in the isolation method. Thus, standardized 
protocols for cell isolation from blood and BAL are required in order to ensure 
homogenous cell populations.224, 225  
The use of well-defined DC subsets and their capacity to induce T cell proliferation 
could give an answer to the heterogeneity of T cells present in LS and non-LS 
sarcoidosis patients. As an example, IRF4+ cDC2s were shown to activate Th17 cells 
in the pulmonary and intestinal mucosa in inflammatory and infectious diseases.55, 116, 
226 Since a Th17 phenotype was observed in sarcoidosis, it is of interest to address if 
cDC2s or any other MNP subset contribute to the skewing of Th17 cells. A summary 
of MNPs contributing to pathogenesis in sarcoidosis is illustrated in Figure 7. 
 
 
Figure 7. Sarcoidosis pathogenesis. A yet unknown antigen is taken up by MNPs of the 
respiratory tract (I). The reaction of MNPs to the antigen is influenced by genetic and 
environmental factors. Upon uptake, MNPs produce cytokines that are released locally and 
into the blood stream (II). This results in local and systemic inflammation and recruitment of 
MNPs to the site of inflammation (III). Exposed macrophages are not able to clear the 
antigen and accumulate due to continuous activation. At the same time, DCs migrate with 
the antigen to the lymph node to activate naïve T cells (IV). Proliferating T cells differentiate 
into Th1 and Th17.1 cells and are released into circulation (V). In the lungs, T cells migrate 
to the site of inflammation. Here, T cells surround the non-necrotic core of macrophages 
(VI). 
 
Taken together, MNPs play an important role in sarcoidosis by producing cytokines, 
forming granulomas and activating T cells. As MNP subsets are highly specialized, 
detailed phenotypic and functional studies are required to dissect the MNP network in 
the sarcoidosis-affected tissue, and in blood. 
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5.2.5 Mononuclear phagocytes in tuberculosis 
Sarcoidosis presents with non-necrotizing granulomas in contrast to tuberculosis (TB), 
that has necrotic granulomas caused by Mycobacterium tuberculosis (Mtb). The 
pathogenesis of TB is better understood than sarcoidosis due to high prevalence of 
TB and the opportunity to use animal models. The knowledge about MNPs derived 
from TB research may help to understand their function and the mechanisms involved, 
which could also facilitate insight into the complex pathogenesis of sarcoidosis. 
TB is the leading cause of death from a single infectious agent. Every year, 10 million 
people get infected. About 1.5 million people died of the consequences of the disease 
in 2018 but the mortality seems to have a descending trend.227 Despite currently 
available antibiotic treatments, drug resistances are increasing highlighting the 
necessity for new and additional treatment options and/or vaccination strategies.  
A special role is attributed to MNPs in Mtb infection as macrophages serve as a 
reservoir and form necrotizing granulomas in the lung parenchyma.228 Upon infection 
with Mtb, AMs as well as pulmonary DCs take up the bacteria and release 
proinflammatory cytokines such as TNF with its dual role contributing to disease 
severity as discussed above.228-231 Additionally, a variety of chemokines are released 
to recruit monocytes, DCs and neutrophils to the site of infection, that potently 
phagocytose the bacteria.228 However, Mtb has developed strategies to escape the 
immune system by inhibiting the fusion of phagosome and lysosome, inducing an anti-
inflammatory program in macrophages and inhibiting the production of reactive 
oxygen species.232, 233 Protected within the phagosome, Mtb replicates and ultimately 
leads to the necrosis of macrophages.234 At the same time, DCs also get infected 
resulting in the maturation of DCs and their migration to the draining lymph node, 
where they activate naïve T cells.235, 236 DCs mainly produce IL-12 and IL-23 skewing 
CD4+ T cells mainly to a Th1 type.237, 238 TB-specific Th1 cells are recruited to the site 
of infection where they accumulate around the necrotizing macrophages trying to clear 
the tissue from infection and produce large quantities of IFNγ.232 The bacteria remain 
contained but alive within the necrotic core protecting the surrounding tissue. At this 
stage, patients suffer from a latent tuberculosis.  
Using this extensive knowledge on MNPs in TB can hint to pathways involved in the 
pathogenesis that ultimately will improve our understanding of sarcoidosis 
pathogenesis.  
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6 MATERIAL AND METHODS 
A detailed description of the materials and methods used in this thesis can be found 
in the respective Papers I-IV. The following section is a general description of the core 
methods and experimental setups used in this thesis. 
 
6.1 ETHICAL CONSIDERATIONS 
In the studies presented in this thesis, all samples were obtained from human blood 
and tissues. All studies have been reviewed and approved by the regional ethical 
review boards in Stockholm and Umeå and were conducted according to the 
Declaration of Helsinki. Prior to participation in our studies, study subjects gave oral 
and written informed consent. While sarcoidosis patients underwent the clinical 
procedure for diagnostic purposes, healthy subjects were volunteering for 
bronchoscopy. Volunteers were treated similarly to patients and, in addition, were 
compensated for their participation. For all study subjects, we handled sensitive data 
from individual persons. Thus, a coding system was used to blind personal data from 
the patient sample at any time. 
 
6.2 STUDY SUBJECTS AND SAMPLE COLLECTION 
For all Papers, healthy volunteers and patients with suspected sarcoidosis were 
recruited to either Norrlands University Hospital, Umeå or Karolinska University 
Hospital, Stockholm to undergo bronchoscopy. The bronchoscopies were performed 
by well-trained and experienced teams of nurses and physicians. A flexible 
bronchoscope was inserted through either nose or mouth into the airways. During the 
bronchoscopy, endobronchial biopsies (EBB) were taken from the major carinas of 
the bronchial tree. Next, a bronchial wash (BW) was performed on the contralateral 
side followed by a bronchoalveolar lavage (BAL) with saline solution to sample the 
proximal and distal bronchial tree, respectively. Additionally, in sarcoidosis patients, 
aspirates from the lung-draining lymph nodes (LLN) were taken using endobronchial 
ultrasound-guided transbronchial needle aspiration (EBUS-TBNA). From all subjects, 
blood samples were taken prior to bronchoscopy (Figure 8). 
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Figure 8. Sampling of sarcoidosis patients and healthy controls. In the studies, healthy 
controls as well as LS and non-LS sarcoidosis patients were sampled. Common for all studies, 
blood was sampled and peripheral blood mononuclear cells (PBMCs) isolated. During 
bronchoscopy, bronchial wash (BW), bronchoalveolar lavage (BAL) and endobronchial 
biopsies (EBB) were sampled. In sarcoidosis patients, the lung-draining lymph nodes (LLN) 
were sampled using endobronchial ultrasound-guided transbronchial needle aspiration 
(EBUS-TBNA). 
 
6.3 PROCESSING OF BLOOD, BW, BAL, EBB AND LLN 
In order to obtain single-cell suspensions for flow cytometric analysis and cell culture, 
human tissue samples were processed. For Paper I and II, blood was collected in 
CPT tubes (BD) and peripheral blood mononuclear cells (PBMC) isolated according 
to the manufacturer’s instructions. Blood in Paper III and IV was collected in heparin 
tubes and plasma collected by centrifugation for 10 min at 600 x g. Whole blood was 
diluted 1:1 with PBS and layered over Ficoll followed by density centrifugation at 900 
x g for 25 min without brake.  
EBBs had a size of around 1mm3 and up to five specimens from the same subject 
were pooled and incubated with 1,4-Dithiothreitol (DTT) followed by digestion with 
collagenase and DNase to obtain a single-cell suspension. For Paper I-IV, BAL and 
BW were filtered and washed with PBS. In Paper II, up to five LLN aspirates were 
pooled, washed and due to red blood cell (RBC) contamination treated with RBC lysis 
buffer. Single-cell suspensions from blood, BAL, BW, EBB and LLN were counted and 
viability assessed using trypan blue exclusion prior to downstream applications. 
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6.4 FLOW CYTOMETRY AND FLUORESCENCE-ACTIVATED CELL SORTING  
Essential to Papers I-IV, was the use of flow cytometry-based analyzers (LSRII and 
LSRFortessa, BD) and sorters (AriaIII and AriaFusion, BD). Flow cytometry has 
revolutionized the field of immunology and has become obsolete in research and 
clinical diagnostics. Common to flow cytometry is the laser excitation of fluorochromes, 
typically conjugated to antibodies targeting surface or intracellular epitopes, that emit 
light at a higher wavelength that is detected by specialized photomultiplier tubes. An 
addition in cell sorters compared to the analyzers is that samples can be further used 
after the staining as cells are deflected by electrodes and collected in tubes.  
For staining of surface antigens, single-cell suspensions were incubated with a fixable 
viability dye followed by validated panels of fluorochrome conjugated antibodies. For 
staining of intracellular epitopes, cells were first fixed and permeabilized before 
incubation with antibodies targeting cytokines and transcription factors.  
 
6.5 IN VITRO STIMULATION OF MNPs 
In Paper I and III, MNPs from blood and BAL were cultured for 3h with or without LPS 
stimulation. In the presence of Brefeldin A (BFA), cytokines were allowed to 
accumulate that could be detected with an intracellular staining. BFA is a protein that 
inhibits protein transport from the endoplasmic reticulum to the GOLGI complex 
resulting in the accumulation of proteins in the cytoplasm. 
 
6.6 RNA ISOLATION AND RNA SEQUENCING  
For Paper III, RNA was isolated from FACS-sorted MNPs from blood and BAL to 
analyze the transcriptome using RNAsequencing (RNAseq). RNA was isolated from 
sorted cells and samples used for RNAseq required an RNA integrity number (RIN) 
higher than 6. Isolated RNA was transcribed to cDNA, amplified and a library created. 
Sequencing was performed using a HiSeq-4000 platform (Illumina) with a 2x150-bp 
pair-end sequencing with a depth of 20 million reads/sample. Sequencing quality was 
assessed using FASTQC and further analysis performed using R. 
 
 
 
  
27 
6.7 T CELL CO-CULTURE 
For Paper IV, FACS-sorted MNPs from blood and BAL were cultured with allogeneic 
T cells from a healthy donor. For this, blood from a buffy coat was used and T cell 
isolated using the RosetteSep T cell enrichment kit (StemCell Technologies). To 
detect proliferation, T cells were labeled with 0.5 µM carboxyfluorescein succinimidyl 
ester (CFSE, Life Technologies). MNPs were co-cultured with CFSE labeled T cells 
for 5 days in a ratio of 1:50. On day 5, phorbol 12-myristate 13-acetate (PMA, 50ug/ml) 
and ionomycin (1ug/ml) were added to the culture in the presence of BFA (10ug/ml) 
for 4h to assess intracellular cytokine production.  
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7 RESULTS AND DISCUSSION 
This thesis was designed to characterize human mononuclear phagocytes (MNPs) in 
the respiratory tract during steady state and sarcoidosis. For this, we first determined 
the distribution of MNPs during steady state conditions (Paper I). Our detailed 
approach by sampling MNPs from the bronchial tissue, the luminal site of the bronchi 
(lavages), and blood identified differences in MNP distribution both within the 
respiratory compartment as well as in comparison to blood. 
In order to answer if MNPs are involved in sarcoidosis pathogenesis, we first 
determined how MNPs are distributed in the same respiratory compartments in 
sarcoidosis patients with and without Löfgren’s syndrome (LS and non-LS) (Paper II) 
and compared it to healthy controls (HCs) (Paper III). Here, we observed important 
differences between non-LS sarcoidosis patients and HCs. In non-LS patients, 
monocytes were the dominating cell subset compared to dendritic cells (DCs). 
Functionally, we observed a highly pro-inflammatory profile in non-LS patients 
compared to LS patients and HCs. In particular monocytes showed high expression 
of genes related to inflammation and of the proinflammatory cytokine tumor necrosis 
factor (TNF). Interestingly, TNF production by pulmonary monocytes predicted which 
patients at time of diagnosis are at risk to develop severe disease (Paper III). 
Additionally, we found respiratory MNPs to induce Th1 cells with potent interferon 
gamma production (Paper IV). Taken together, these results highlight the importance 
of studying respiratory MNPs in detail and identifies MNPs as main drivers of 
pathogenesis in sarcoidosis. Detailed information is described in the following sections 
and in the original Papers I-IV. 
 
7.1 IDENTIFICATION AND HETEROGENEITY OF RESPIRATORY MNPs 
In order to compare monocytes and DCs across studies and compartments using flow 
cytometry, we applied similar staining panels and gating strategies as exemplified in 
Figure 9A. MNPs were identified as HLA-DR+ and lineage negative. Lineage markers 
excluded T cells, B cells, NK cells, and neutrophils. Amongst MNPs, CD123+ 
expression was used to identify plasmacytoid DCs (pDCs). CD11c+ MNPs and 
expression of CD14 and CD16 identified classical, intermediate, and non-classical 
monocytes. Conventional DCs were defined as CD14-CD16- and expression of 
CD141 and CD1c identified cDC1s and cDC2s, respectively (Figure 9A). In 
bronchoalveolar lavage (BAL), alveolar macrophages (AMs) were identified as side 
scatter high and by their autofluorescence. Using the same staining panel and gating 
strategy in blood and the respiratory tract, we used the same nomenclature for 
monocytes in both compartments. However, in the respiratory tract, it cannot be 
excluded that CD14+ and CD16+ monocytes may in fact be monocyte-derived cells.111, 
114, 115 Monocytes are highly plastic and upon migration to the tissues differentiate into 
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monocyte-derived dendritic cells (mo-DCs) or macrophages.67 In BAL from HCs, mo-
DCs were identified as CD14 and CD1c expressing cells and comprised about 30% 
of CD14+ monocytes (Figure 9B). In LS and non-LS sarcoidosis patients, about 20% 
of CD14+ cells in BAL expressed CD1c (Figure 9B). This might be the result of a 
higher migratory potential of monocytes to the respiratory tract as a response to the 
inflammation in sarcoidosis. Differences in frequencies of mo-DCs in sarcoidosis 
patients and HCs could indicate distinct functional properties.  
 
Figure 9. Phenotype of MNPs in bronchoalveolar lavage. (A) Representative plots of a 
non-LS patient to identify different MNP subsets in cells obtained by bronchoalveolar lavage 
(BAL). SSC: side scatter; FSC: forward scatter; AF: autofluorescence (B) Identification of 
mo-DCs as CD14+ CD1c+ cells in BAL. Graph shows the frequencies of mo-DCs in HCs 
compared to LS and non-LS patients. 
 
In the different compartments of the respiratory tract as well as blood, monocytes and 
DCs could be identified at varying frequencies (Figure 10A). The most striking 
differences in distribution were observed comparing MNPs from blood and the 
respiratory tract. In HCs and sarcoidosis patients, frequencies of HLA-DR+ MNPs 
increased from the proximal to the distal part of the lower airways. The alveoli are 
functionally important and responsible for the uptake of oxygen. To ensure organ 
function, MNPs could be preferentially seeded in the distal area to protect the 
epithelium from invading pathogens. The most common subset in blood were classical 
monocytes (CMs) that egress from the bone marrow and undergo differentiation into 
intermediate (IMs) and non-classical monocytes (NCMs).70 In LS and non-LS 
sarcoidosis, frequencies of circulating IMs were elevated likely due to the persistent 
inflammation (Figure 10B). Differentiation of CMs to IMs is accelerated by 
inflammation and an increased frequency of blood IMs is observed in other infectious 
or inflammatory diseases including sarcoidosis.215, 217, 239, 240 We also observed an 
increase of IMs in BAL of non-LS patients compared to HCs indicating local pulmonary 
inflammation in sarcoidosis (Figure 10B). Importantly, we identified IMs to be 
predictors of disease outcome. For this, we followed patients over two years after the 
diagnosis was established. We found that patients with high frequencies of blood IMs 
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at time of diagnosis were more likely to develop chronic disease than patients with 
lower frequencies of blood IMs at time of diagnosis (Figure 10C). This finding 
highlights the importance of dissecting the MNP network in the respiratory tract during 
sarcoidosis.  
 
Figure 10. Distribution of monocytes in blood and the respiratory tract during steady 
state and sarcoidosis. (A) Pie charts show distribution of classical (blue), intermediate 
(green) and non-classical (teal) monocytes in blood, bronchoalveolar lavage (BAL), 
endobronchial biopsies (EBB), and lung-draining lymph nodes (LLN) in healthy controls 
(HCs) and non-LS sarcoidosis patients. Number of subjects included are indicated in the 
center of the pie chart. (B) Frequencies of intermediate monocytes in blood and BAL of HCs 
and non-LS sarcoidosis patients. Statistical analysis was performed using the non-
parametric Mann Whitney U test. *p < 0.05, ****p < 0.0001. (C) Graph shows predictive 
modelling for frequencies of intermediate monocytes in blood of sarcoidosis patients at time 
of diagnosis using linear regression. OR: odds ratio. 
 
Investigating the lung-draining lymph nodes (LLNs) in sarcoidosis is a unique 
possibility to study the site of T cell priming. We performed the first detailed analysis 
of MNPs in the LLN of LS and non-LS patients using flow cytometry.214 As expected, 
MNPs in the LLN are rare (ca. 1% of total cells). Interestingly, we observed a difference 
in distribution of MNPs between LS and non-LS sarcoidosis patients, primarily caused 
by plasmacytoid DCs (pDCs). In non-LS patients, pDCs comprise of about 20% of 
HLA-DR+ cells, while in LS patients it is only 5% on average. Activated pDCs produce 
type I interferons that in turn activate IFNγ producing Th1 cells, the main drivers of 
sarcoidosis.196 This shift towards monocytes in the LLNs in LS patients compared to 
non-LS patients indicates important differences that may have an impact on disease 
outcome.200 
In order to optimally interact with and activate T cells, MNPs have to upregulate 
surface expression of HLA-DR for antigen presentation and co-stimulatory receptors 
such as CD80 or CD86, a process called maturation.6, 241 Overall, MNPs were most 
mature in the respiratory tract compared to blood. Surprisingly, expression of CD80 
  
31 
and HLA-DR was lower in LLNs compared to BAL in sarcoidosis patients. Increased 
maturation in the lung environment could indicate an ongoing inflammation leading to 
the maturation of MNPs.242, 243 Supportive of this theory is the upregulation of CCR7, 
the chemokine receptor mediating the migration to the draining lymph nodes.122 
In summary, there are distinct differences in distribution and phenotype between DCs 
and monocytes from blood, lung or lung-draining lymph nodes highlighting the 
importance of studying MNPs subsets side-by-side. 
 
7.2 TRANSCRIPTOME OF PULMONARY MNPs DURING STEADY STATE AND 
SARCOIDOSIS 
Flow cytometry is a powerful tool to reliably study immune cells. However, it also has 
its limitations. A caveat of flow cytometry is the use of predefined markers to identify 
MNPs. Particularly in tissues, monocytes and DCs share surface markers that in blood 
served to distinguish MNPs.18 Using RNAsequencing (RNAseq) allows for an 
unbiased approach to study MNPs and with a higher resolution as the entire 
transcriptome is quantified. RNAseq analyses have revolutionized our understanding 
of cell heterogeneity, ontogeny and tissue specificity has revolutionized.244 We 
performed RNAseq on whole populations of FACS-sorted monocytes and DCs from 
blood and BAL as well as AMs. The advantage of doing RNAseq on sorted MNP 
subsets compared to bulk sequencing of total BAL cells, is to find important signatures 
in rare subsets that would be masked by the abundance of AMs and T cells.245-247 
Similar to the phenotype of MNPs, we observed pronounced differences in gene 
expression between blood and BAL MNPs independent of whether cells were derived 
from sarcoidosis patients or HCs. A total of 2603 genes were differentially regulated 
between blood and BAL MNPs (Figure 11A). Common to all MNPs obtained from 
BAL, expression of genes related to the inflammatory response (CD40, TNF, IL1A, 
CSFR1, NFKB1, CD274), chemotaxis (CCL2, CCL8, CCL19, CCL20, CCR6), and cell 
differentiation (CD40, CCR7, AXL, TGFBR1, CD207) was higher compared to blood 
MNPs. However, also genes related to angiogenesis (VEGFA, PDGFA, ITGAV), 
coagulation (CD9, C3, FN1) and signaling pathways were upregulated as assessed 
by gene set enrichment analysis (Figure 11B). We confirmed these RNAseq results 
on the protein level for CCR6, CCR7, and CD207 (langerin), all markers predominantly 
expressed by cDC2s. CCR6 is highly expressed by BAL cDC2s in both sarcoidosis 
patients and HCs. Its cognate ligand is CCL20, which is highly expressed by BAL 
MNPs suggesting that the recruitment of cDC2s is mediated by other pulmonary 
MNPs. Since CCR6+ cDC2s are not restricted to sarcoidosis patients or HCs, it can 
be assumed that CCL20 is constitutively expressed by epithelial cells and MNPs.248-
251 The continuous recruitment of cDC2s could be a mechanism to rapidly respond to 
infiltrating pathogens to the lung tissue.252 
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Figure 11. Differential gene expression of blood and BAL MNPs from HCs and non-LS 
patients. (A) Volcano plot shows differentially expressed genes (red dots) that are common 
to all MNP subsets from blood and BAL of healthy individuals and sarcoidosis patients. (B) 
Differentially expressed genes from different MNP subsets were allocated to pathways in 
the gene set enrichment analysis. MNPs between blood and BAL were compared in HCs 
and non-LS patients.  
 
Next, we analyzed differences in gene expression in MNPs from sarcoidosis patients 
and HCs. Both in blood and BAL MNPs, we observed that genes related to the TNF 
and IL-6 pathways were upregulated in cells from sarcoidosis patients compared to 
HCs. Additionally, genes in response to IFNγ were upregulated in MNPs from 
sarcoidosis patients confirming previous observations.253 This is likely a response to 
the excessive activation of T cells in sarcoidosis and highlights the key role of T cells 
in sarcoidosis. Particularly, genes of the TNF pathway were highly upregulated in 
monocytes of non-LS patients compared to HCs. In contrast, AMs showed 
upregulated genes related to the reactive oxygen species pathway, TGF-β or the fatty 
acid metabolism. Interestingly, CSF1 was upregulated by MNPs in BAL of non-LS 
patients that favor the differentiation of alternatively activated macrophages.254 
Supportive of this, MNPs in BAL of non-LS patients also expressed high levels of TGF-
β compared to controls, also favoring alternatively activated macrophage 
polarization.255 Here, future analyses using single-cell RNAseq may reveal the 
heterogeneity of AMs in sarcoidosis as shown for other pulmonary diseases.256-261 It 
is likely that the balance between pro- and anti-inflammatory macrophages contribute 
to disease progression and resolution. Collectively, these findings mark significant 
differences between AMs and monocytes in the lungs of sarcoidosis patients. 
 
  
33 
7.3 FUNCTIONAL PROPERTIES OF MNPs DURING STEADY STATE AND 
SARCOIDOSIS 
To confirm this inflammatory profile, we performed functional experiments of MNPs 
and assessed TNF expression on a protein level in monocytes, macrophages and 
DCs. Cells from blood and BAL were cultured for 3 hours with lipopolysaccharide 
(LPS) or left unstimulated in the presence of BFA to allow accumulation of cytokines 
intracellularly. As expected, blood monocytes from HCs and sarcoidosis patients 
produced TNF only after LPS stimulation. In contrast, BAL monocytes produced TNF 
also without stimulation. Intrinsic TNF production in sarcoidosis patients was observed 
before and was mostly attributed to macrophages.207, 208, 262 The advantage of our 
experimental setup is the use of flow cytometry compared to ELISA used in previous 
studies. It was assumed that AMs are the major source of TNF as those are the most 
abundant cell type in BAL.211 However, our detailed approach to determine TNF 
production by individual MNP subsets, in fact, showed that higher frequencies of 
pulmonary monocytes rather than AMs or DCs produced TNF (Figure 12A). 
Additionally, frequencies of unstimulated TNF producing BAL monocytes was 
significantly higher in non-LS patients compared to HCs and LS patients. Importantly, 
non-LS patients with high frequencies of TNF producing intermediate monocytes were 
more likely to develop progressive disease in a prediction model (Figure 12B). We 
did not find that AMs predicted disease outcome as previously described.209 These 
data highlight the importance of studying pulmonary monocytes in sarcoidosis. Even 
though monocytes and DCs are rare cells in the lungs compared to AMs, they 
contribute significantly to disease pathogenesis in sarcoidosis. 
In contrast, we found LS sarcoidosis patients to have more IL-6 producing monocytes 
compared to non-LS patients. Comparing intrinsic TNF and IL-6 production by 
monocytes showed a positive correlation in non-LS patients while there was a trend 
towards a negative correlation in LS patients (Figure 12C). These data suggest a 
distinct cytokine profile in LS and non-LS sarcoidosis patients indicating differences in 
the pathogenesis. This has raised the question to view LS and non-LS sarcoidosis as 
two distinct disease entities.12 IL-6 is a driver of Th17 cell differentiation, which were 
shown to be accumulated in LS patients.197, 263 
Anti-TNF treatment is currently used as a 3rd line treatment in sarcoidosis. Previous 
studies showed that patients with high serum TNF concentrations and higher numbers 
of circulating intermediate monocytes are more likely to benefit from anti-TNF 
treatment.210, 264, 265 In our studies, we aimed to determine if intrinsic TNF expression 
can also be used to predict success of anti-TNF therapy. Despite few patient numbers 
at this time, our preliminary data is interesting. We measured TNF expression by 
pulmonary MNPs in patients with progressive disease prior to and after anti-TNF 
treatment (infliximab). Prior to anti-TNF treatment, we found a range of intrinsically 
TNF producing MNPs in the patients that may be skewed due to their treatment with 
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corticosteroids at that time. To our surprise, after anti-TNF treatment, we observed 
that monocytes from BAL of all patients expressed TNF without stimulation (on 
average 60% of monocytes) (Figure 12D). These data indicate that despite the anti-
inflammatory treatment, cells are still highly inflammatory and may be one reason for 
a relapse after discontinuation of anti-TNF treatment.266 TNF expression by pulmonary 
monocytes may therefore be a tool to determine duration of anti-TNF treatment. Anti-
TNF treatment is well established in rheumatoid arthritis and Crohn’s disease.267, 268 
Among the risks of treatment with biologicals is, however, the development of anti-
drug antibodies (ADA).269 To prevent ADA production, low-dose corticosteroids or 
methotrexate accompany anti-TNF treatment resulting in further side effects.270 Thus, 
it is crucial to identify sarcoidosis patients that would suffer from severe disease and 
initiate targeted treatment early on to prevent excessive inflammation. 
 
Figure 12. TNF expression by respiratory MNPs in non-LS sarcoidosis patients. (A) 
Concatenated pseudocolor plot shows intracellular TNF expression in AMs, CMs and cDC2s 
from one non-LS patient. Cells were cultured for 3h without stimulation. (B) Violin plots show 
TNF expression by unstimulated IMs and AMs at time of diagnosis and grouped based on 
the clinical outcome after two years. (C) Correlation of IL-6 and TNF expression by BAL CMs 
in non-LS (blue squares) and LS patients (red triangles). (D) Intracellular TNF expression 
by BAL CMs in non-LS patients prior to infliximab treatment and after six months. Patients 
are color-coded and the line connects each patient before and after infliximab treatment. 
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T cells are expanded in sarcoidosis patients and are likely critical in pathogenesis as 
they are a major source of IFNγ, that is abundantly expressed in sarcoidosis patients. 
MNPs as antigen-presenting cells are responsible for T cell activation. Hence, we 
wanted to assess the ability of MNPs from sarcoidosis patients to induce T cell 
proliferation. FACS-sorted MNPs from blood and BAL of non-LS patients were co-
cultured with allogeneic T cells from a healthy donor. Overall, MNPs from blood 
induced more T cell proliferation than the respective MNP subset from BAL (Figure 
13A+B). Blood and BAL cDC2s were altogether better at inducing T cell proliferation 
compared to cDC1s followed by classical and intermediate monocytes and alveolar 
macrophages that did not induce T cell proliferation (Figure 13B). An exception were 
classical monocytes from BAL, that potently induced T cell proliferation. This could be 
due to the presence of CD1c+ mo-DCs among the CD14+ monocytes. Thus, it cannot 
be excluded that a fraction of cells comprised of mo-DCs that are superior in inducing 
T cell proliferation compared to tissue monocytes.115 In our cohort, 20% of monocytes 
were mo-DCs as assessed by CD1c expression (Figure 9B). Despite the low 
frequency of mo-DCs, their ability to induce T cell proliferation was similar to bona fide 
DCs. This highlights another important feature of monocytes and monocyte-derived 
cells in sarcoidosis. 
 
Figure 13. T cell proliferation and differentiation induced by BAL MNPs. (A) 
Representative plot of T cell proliferation assessed by CFSE dilution after co-culture of blood 
and BAL cDC2s with allogeneic T cells. (B) Summary of induced T cell proliferation after co-
culture with MNP subsets from blood and BAL. Bar graphs show mean ± SEM. (C) 
Representative plot shows expression of transcription factors Tbet and RORγt in proliferated 
CD4+ T cells after co-culture with BAL cDC2s. Further, plots show IL-17 and IFNγ expression 
after restimulation with PMA/ionomycin. Pie charts illustrate the cytokine expression in 
proliferated Tbet+ and Tbet+RORγt+ cells. 
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Further, we wanted to assess how T cells differentiate upon activation by MNPs from 
sarcoidosis patients. We hypothesized that MNPs should induce T cells similar to 
those found in BAL of sarcoidosis patients. These T cells characterized by their 
expression of CXCR3 and CCR6 are termed Th17.1 cells and excelled at producing 
IFNγ.198, 199, 271, 272 As shown in the respective studies, chemokine receptors are co-
expressed by Th1 and Th17 cells.198, 199 Thus, we used Th1 and Th17 specific 
transcription factors and cytokines instead to determine the T cell fate.273, 274 Blood 
and BAL MNPs from sarcoidosis patients mostly induced Tbet expressing Th1 cells 
producing mainly IFNγ (Figure 13C). Between 5-10% of proliferated T cells also 
expressed Tbet together with RORγt. Upon restimulation, T cells mostly produced 
IFNγ followed by IL-17 suggesting the presence of Th17.1 cells as observed in vivo 
(Figure 13C).198, 199 If those cells resemble Th1 cells that acquire a Th17-like 
phenotype or vice versa remains to be elucidated in further studies. However, this data 
highlights the plasticity of T cells, particularly during inflammatory conditions.275, 276 
Hence, it is crucial to also understand how MNPs are involved in determining the T 
cell fate. Altogether, we could show the potential of MNPs from sarcoidosis patients 
to induce pathogenic Th17.1 cells in vitro. This offers a novel way to study this subset 
of T cells in the pathogenesis of sarcoidosis.  
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8 CONCLUSIONS 
The studies presented in this thesis were designed to unravel the distribution and 
function of human mononuclear phagocytes (MNPs) in the respiratory tract during 
steady state and sarcoidosis. Pulmonary MNPs serve as gatekeepers in the lungs as 
they constantly face the challenge to either maintain tolerance or initiate immune 
responses. The role of MNPs in tissues has been extensively studied in mouse 
models. However, detailed knowledge about human pulmonary MNPs is scarce as 
tissues are often acquired from patients with pulmonary diseases. Hence, retrieving 
samples from healthy volunteers from different anatomical locations along the 
respiratory tract will pave the way to unravel the complexity of MNPs in the lungs. 
Understanding the distribution and function of MNP subsets during steady state is 
necessary to identify factors involved in pulmonary diseases, such as sarcoidosis. In 
sarcoidosis, reliable mouse models are still lacking that could identify pathways 
involved in disease pathogenesis. Hence, an in-depth characterization of MNPs from 
the respiratory tract comparing steady state and sarcoidosis will help uncover 
mechanisms involved in disease pathogenesis. This will help to develop new therapy 
options and improve the patient’s quality of life. 
 
Altogether, the main conclusions of this thesis are as follows: 
• MNPs have a distinct distribution, phenotype and transcriptome based on their 
anatomical location with major differences between blood and the respiratory 
tract during both steady state and sarcoidosis (Paper I + II + III). 
 
• The distribution of monocytes and DCs in sarcoidosis helps to predict which 
patients will develop progressive disease (Paper III). 
 
• Pulmonary monocytes contribute significantly to inflammation in sarcoidosis by 
producing TNF, which is also associated with disease progression (Paper III). 
 
• Circulating and pulmonary DCs from sarcoidosis patients effectively induce T 
cell proliferation with a Th1 phenotype (Paper IV). 
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9 FUTURE DIRECTIONS 
The characterization of pulmonary MNPs during steady state and sarcoidosis as 
outlined in this thesis is a first step towards improving our knowledge on how the lungs 
maintain homeostasis and react during immune challenges. However, several 
questions remain that should be addressed in future studies. 
We have successfully established methods to characterize MNPs in the human 
respiratory tract. The identification of MNPs was based on surface receptors found in 
blood that could be detected by flow cytometry. We and others have detected 
overlapping phenotypic characteristics between MNPs in the respiratory tract.114, 115, 
129, 277 Hence, a more unbiased approach using single-cell RNAseq would help to 
characterize MNP populations in-depth as described for circulating MNPs.94-96, 244 
Together with bioinformatic tools, the mononuclear phagocyte landscape will change 
and likely reveal even more heterogeneity.278, 279 
A detailed study on a single-cell level comparing MNPs from the alveolar space with 
MNPs from the lung parenchyma would be of interest. This could address the question 
to which extent cells retrieved by bronchoalveolar lavage reflect cells from the lung 
parenchyma. When studying immune cells on a single-cell level in the lungs, it would 
also be of interest to study the kinetics and migration of MNPs to and from the tissue. 
Upon controlled experimental inflammation280, 281 or infection,282 studies using labeled 
cells70, 283 would allow to track single-cells to determine their potential to migrate into 
tissues. This could also answer the question if MNPs transmigrate through the 
epithelial layer to the draining lymph nodes. 
As a follow-up to the transcriptome analysis, pathways related to the energy 
metabolism, coagulation, and signaling pathways related to cell proliferation of MNPs 
from sarcoidosis patients can be further explored. That could answer at what stage 
the fate of sarcoidosis patients are skewed towards either disease resolution or 
disease progression. 
One major remaining challenge in sarcoidosis research remains to identify the 
antigen(s) that initiate(s) disease and result in granuloma formation. Identification of 
one or several antigens could help explain the differences observed in cytokine 
production by MNPs in LS and non-LS sarcoidosis patients. MNPs could be 
specifically stimulated with the antigen that would result in a distinct T cell response. 
Currently in use are mouse models and in vitro systems based on candidate 
antigens.284 Studying the immunopathogenesis of sarcoidosis in model systems 
allows for the identification of novel factors contributing to disease progression. That 
knowledge could be exploited to develop therapeutic interventions to help the immune 
system clear the antigen and ultimately resolve inflammation. 
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